Cubist Systematic Strategies’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Cubist Systematic Strategies’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,275	Closed	-$79K	–	2339
2018 Q3	$79K	Buy	+1,275	New	+$86.3K	﹤0.01%	1640
2017 Q4	–	Sell	-1,418	Closed	-$164K	–	2149
2017 Q3	$164K	Buy	+1,418	New	+$149K	0.01%	1515
2017 Q2	–	Sell	-990	Closed	-$122K	–	1928
2017 Q1	$122K	Buy	+990	New	+$130K	0.01%	1346
2016 Q1	–	Sell	-290	Closed	-$59K	–	1897
2015 Q4	$59K	Sell	290 -3,997	-93%	-$715K	﹤0.01%	1577
2015 Q3	$623K	Buy	4,287 +3,697	+627%	+$679K	0.03%	818
2015 Q2	$125K	Buy	590 +243	+70%	+$59.6K	0.01%	1581
2015 Q1	$80K	Buy	347 +227	+189%	+$54.9K	﹤0.01%	1701
2014 Q4	$28K	Buy	+120	New	+$25.7K	﹤0.01%	1811

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's BLCM Position: Q4 2018 in Review

Cubist Systematic Strategies sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2018, closing a stake of 1,275 shares — an estimated $79K sold.

Cubist Systematic Strategies first reported a position in BLCM in Q4 2014 and held it in 8 quarters. The position peaked at $623K in Q3 2015. 92 funds tracked by Wall St. Rank hold BLCM as of Q4 2018.

Cubist Systematic Strategies reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Cubist Systematic Strategies sold 1,275 Bellicum Pharmaceuticals, Inc. shares in Q4 2018, an estimated $79K.
Cubist Systematic Strategies first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 8 quarters.
Cubist Systematic Strategies's Bellicum Pharmaceuticals, Inc. position peaked at $623K in Q3 2015.
92 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2018.

Based on Cubist Systematic Strategies's 13F filing for Q4 2018, filed 14 Feb 2019.